Relation between HLA-DP/DQ Polymorphisms, Serum IP-10 and Response to Direct Acting Antiviral Therapy among HCV Infected Patients.

HCV infection represents a worldwide health problem with many attempts to control. This study aimed to assess the relation between HLA-DQ-rs3920 SNP, HLA-DP-rs3077 SNP, serum IP-10 levels and response to direct acting antiviral (DAA) drugs among HCV infected Egyptian patients. The study included 100 HCV infected patients (received sofosbuvir, Daclatsvir and Ribavirin) and 50 apparently healthy volunteers as controls. Serological, hematological and viral investigations were done to all participants. Whole DNA was extracted, HLA-DQ-rs3920 SNP and HLA-DP-rs3077 SNP were evaluated using RT-PCR and serum IP-10 levels were determined. Higher frequencies of HLA-DQ rs3920 AG and HLA-DP rs3077 AA variants was observed among HCV infected patients (P<0.001* and P=0.029*, respectively). There was a statistically significant association between both genotypes and response to DAA. However, HLA-DQ rs3920 A allele was markedly expressed among non-responders group and could be correlated with resistance to DAA therapy. IP-10 levels were significantly decreased among the non-responder group with 95% sensitivity and 15% specificity. We concluded that HLA-DP-rs3077 and/or HLA-DQ-rs3920 SNP may represent independent predictors for susceptibility to infection and response to direct antiviral drugs among HCV infected Egyptian patients. Serum IP-10 could be a predictive marker for disease progression and response to DAA.